Genotypic analysis of HIV-1 coreceptor usage

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1007/978-3-540-78358-9_4
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).

  2010cited by this paper
• Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage.

  2010cited by this paper
• Improved prediction of HIV‐1 coreceptor usage with sequence information from the second hypervariable loop of gp120.

  2010cited by this paper
• Novel approaches to inhibiting HIV-1 replication.

  2010cited by this paper
• Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue

  2010cited by this paper
• Prediction of Co-Receptor Usage of HIV-1 from Genotype

  2010cited by this paper
• Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing

  2010cited by this paper
• Can the further clinical development of bevirimat be justified?

  2010cited by this paper
• Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.

  2010cited by this paper
• Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.

  2010cited by this paper
• Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.

  2010cited by this paper
• Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies

  2010cited by this paper
• Current status and challenges of antiretroviral research and therapy.

  2010cited by this paper
• CCR5 Antagonists: Host-Targeted Antiviral Agents for the Treatment of HIV Infection, 4 Years on

  2010cited by this paper
• Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.

  2010cited by this paper
• Understanding and managing the adverse effects of antiretroviral therapy.

  2010cited by this paper
• Molecular basis of human immunodeficiency virus drug resistance: an update.

  2010cited by this paper
• Genotypic determination of HIV-1 tropism in the clinical setting

  2010cited by this paper
• Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and “Deep” Sequencing to Plasma RNA and Proviral DNA

  2010cited by this paper
• Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat

  2010cited by this paper
• Virus Entry via the Alternative Coreceptors CCR3 and FPRL1 Differs by Human Immunodeficiency Virus Type 1 Subtype

  2009cited by this paper
• Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women

  2009cited by this paper
• The biology of CCR5 and CXCR4

  2009cited by this paper
• The Challenge of Finding a Cure for HIV Infection

  2009cited by this paper
• Improvement in the determination of HIV‐1 tropism using the V3 gene sequence and a combination of bioinformatic tools

  2009cited by this paper
• Performance of Genotypic Coreceptor Measurement Using Geno2pheno[coreceptor] in B- and non-B HIV Subtypes in a Large Cohort of Therapy-experienced Patients in Germany

  2009cited by this paper
• Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility

  2009cited by this paper
• Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

  2009cited by this paper
• Robust Supervised and Unsupervised Statistical Learning for HIV Type 1 Coreceptor Usage Analysis

  2009cited by this paper
• Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation

  2009cited by this paper
• Current tests to evaluate HIV-1 coreceptor tropism

  2009influential reference
• Bioinformatische Unterstützung der Auswahl von HIV-Therapien

  2009cited by this paper
• [A new human immunodeficiency virus derived from gorillas].

  2009cited by this paper
• A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

  2009cited by this paper
• Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif

  2009cited by this paper
• Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C.

  2009cited by this paper
• Novel targets for anti-retroviral therapy.

  2009cited by this paper
• Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

  2009cited by this paper
• Implications of Nef: host cell interactions in viral persistence and progression to AIDS.

  2009cited by this paper
• HIV-1 Viral Subtype Differences in the Rate of CD4+ T-Cell Decline Among HIV Seroincident Antiretroviral Naive Persons in Rakai District, Uganda

  2009cited by this paper
• which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. When is it time for reverse transcription to start and go?

  2009cited by this paper
• V3 Loop Sequence Space Analysis Suggests Different Evolutionary Patterns of CCR5- and CXCR4-Tropic HIV

  2009cited by this paper
• Comparison of Human Immunodeficiency Virus Type 1 Tropism Profiles in Clinical Samples by the Trofile and MT-2 Assays

  2009cited by this paper
• X-ray structures of the hexameric building block of the HIV capsid.

  2009cited by this paper
• Immunoregulatory effects of HIV‐1 Nef protein

  2009cited by this paper
• A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors

  2009cited by this paper
• Toward an AIDS Vaccine

  2008cited by this paper
• Novel mechanisms of HIV protease inhibitor resistance

  2008cited by this paper
• Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

  2008cited by this paper
• Weighted OBT Susceptibility Score (wOBTSS) is a Stronger Predictor of Virological Response at 48 Weeks than BL Tropism Result in MOTIVATE 1 and 2

  2008cited by this paper
• Improved Detection of X4 Virus by V3 Genotyping: Application to Plasma RNA and Proviral DNA

  2008cited by this paper
• Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.

  2008cited by this paper
• Coreceptor Tropism Can Be Influenced by Amino Acid Substitutions in the gp41 Transmembrane Subunit of Human Immunodeficiency Virus Type 1 Envelope Protein

  2008cited by this paper
• Multi-task learning for HIV therapy screening

  2008cited by this paper
• The development and impact of 454 sequencing

  2008cited by this paper
• Performance of a Population-Based HIV-1 Tropism Phenotypic Assay and Correlation With V3 Genotypic Prediction Tools in Recent HIV-1 Seroconverters

  2008cited by this paper
• Correlated mutations at gp120 positions 322 and 440: Implications for gp120 structure

  2008cited by this paper
• Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism

  2008cited by this paper
• Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses.

  2008cited by this paper
• Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes

  2008cited by this paper
• HIV coreceptor phenotyping in the clinical setting.

  2008cited by this paper
• Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

  2008cited by this paper
• Update of the Drug Resistance Mutations in HIV-1.

  2008cited by this paper
• HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

  2008influential reference
• HIV-2: the forgotten AIDS virus.

  2008cited by this paper
• Inferring Viral Tropism from Genotype with Massively Parallel Sequencing: Qualitative and Quantitative Analysis

  2008cited by this paper
• Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41

  2008influential reference
• HIV-1 coreceptor usage prediction without multiple alignments: an application of string kernels

  2008cited by this paper
• Maraviroc for previously treated patients with R5 HIV-1 infection.

  2008influential reference
• Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.

  2008cited by this paper
• HIV coreceptors: from discovery and designation to new paradigms and promise.

  2007cited by this paper
• Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use

  2007cited by this paper
• Elite HIV controllers: myth or reality?

  2007cited by this paper
• Bioinformatics prediction of HIV coreceptor usage

  2007influential reference
• HIV entry inhibitors.

  2007influential reference
• Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations

  2007cited by this paper
• Genotypic coreceptor analysis.

  2007cited by this paper
• An update in the development of HIV entry inhibitors.

  2007cited by this paper
• Is HIV-1 evolving to a less virulent form in humans?

  2007cited by this paper
• Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection

  2007cited by this paper
• HIV genetic diversity: biological and public health consequences.

  2007influential reference
• Structural Descriptors of gp120 V3 Loop for the Prediction of HIV-1 Coreceptor Usage

  2007influential reference
• 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007)

  2007cited by this paper
• HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

  2007cited by this paper
• Baseline HIV type 1 coreceptor tropism predicts disease progression.

  2007cited by this paper
• A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1

  2007cited by this paper
• Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates

  2007influential reference
• HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads.

  2007cited by this paper
• Predicting HIV Coreceptor Usage on the Basis of Genetic and Clinical Covariates

  2007influential reference
• HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays.

  2007cited by this paper
• An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.

  2007cited by this paper
• Survival of blood donors and their spouses with HIV-1 subtype E (CRF01 A_E) infection in northern Thailand, 1992–2007

  2007influential reference
• A Reliable Phenotype Predictor for Human Immunodeficiency Virus Type 1 Subtype C Based on Envelope V3 Sequences

  2006cited by this paper
• Long-term non-progressors--international study recruiting.

  2006cited by this paper
• Pneumocystis pneumonia--Los Angeles.

  2006cited by this paper
• Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism

  2006influential reference
• HIV and the chemokine system: 10 years later

  2006cited by this paper
• The Socio-Economic Impact of HIV/AIDS in Swaziland

  2006influential reference
• Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART.

  2006cited by this paper
• Immunopathogenesis of acute AIDS virus infection.

  2006cited by this paper

• Генетические факторы, влияющие на проникновение ВИЧ в клетку-мишень

  2019cites this paper
• Genetic factors influencing HIV entry into target cells

  2019cites this paper
• Comparison of two genotypic algorithms to determine HIV‐1 tropism *

  2008cites this paper